MARKET WIREStockInvest.us • 21h ago
Ensysce Biosciences Stock Price Forecast. Should You Buy ENSC?StockInvest.us report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
Why ENSC Stock dropped -9.24% Today — RQD Quant Desk Flash
$0.38 -9.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.37
Ensysce Biosciences Inc. (ENSC) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $8.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ENSC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ENSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Ensysce Biosciences Inc. (NASDAQ: ENSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.38 (-9.24% 1D, market cap $8.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ENSC ranks #812 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ENSC compare to CURX and MBRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENSC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CURX (Curanex Pharmaceuticals Inc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and MBRX (Moleculin Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $8.3M). Among the 5-stock peer group, ENSC leads on earnings multiple (N/A) while ENSC leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ENSC?
▼
Per ENSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001716947), Ensysce Biosciences Inc. generated $5.1M in revenue (-2.8% YoY), -$10.2M in net income, and -$7.9M in free cash flow against $7.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.37 (-1.85%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENSC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY ENSC SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (30% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.57-12.3% Next Q
38
Q2 (-2Q)Grade E$0.50-10% Next Q
35
Q3 (-1Q)Grade E$0.45-15.6% Next Q
33
CurrentGrade E$0.38-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ENSC Turnaround Squeeze
While ENSC currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.40) forces dealer call-delta covering toward $2.34.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENSC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ENSC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ENSC Stock dropped -9.24% Today — RQD Quant Desk Flash
Ensysce Biosciences Inc. (ENSC) dropped -9.24% to $0.38, trading at 8% of its 52-week range ($0.23 – $2.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 8% of its 52-week range ($0.23 – $2.23) with RSI-14 at 41.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.38 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ENSC Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, DubaiYahoo Finance report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Australia • 1d ago
Ensysce Biosciences, Inc. (ENSC) Seasonal returns chartYahoo Finance Australia report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Ensysce Biosciences (ENSC) Slips 2.99% to $0.50 as Micro-Cap Biotech Tests Lower Support - IV Expansion Alerthttps://www.siam.in/ report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 1d ago
Ensysce Biosciences (ENSC) Edges Higher: Shares Gain 2.19% to $0.44 - Hull Moving Averagehttps://www.dars.gov.et/ report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Pasithea Therapeutics Corp. (KTTA) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
CATALYSTwww.dars.gov.et • 1d ago
Ensysce Biosciences (ENSC) Gains 4.29% to $0.52 as Shares Press Toward Resistance - Put Wallwww.dars.gov.et report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 14d ago
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.
MARKET WIREBenzinga • 19d ago
12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands at
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENSC)
- ✓Walkthrough of ENSC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ENSC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.52%▲ ASCENDING CHANNEL
2026-11-03O $0.44H $0.44L $0.38C $0.38VOL 109.0K
RES: $0.67SUP: $0.25SMA50: $0.45SMA200: $0.43
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ENSC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ENSC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ENSC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENSC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENSC)
Health Care Rank #812 of 1015
⚔️ CURX vs ENSC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ENSC vs. CURX, MBRX, TCRT, SNGX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Ensysce Biosciences Inc. (ENSC) ranks #812 by composite RQD confidence (30/100, grade E) and #908 by equity capitalization ($8.2M). Within this direct 5-issuer industry benchmark cohort, ENSC leads on earnings valuation at N/A trailing P/E, while ENSC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SNGX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ENSC at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENSC
ACTIVE
Ensysce Biosciences Inc. | E | 30/100 | — | — | -35.0% | -9.24% | $8.2M | Benchmark Subject |
| CURX Curanex Pharmaceuticals Inc | D- | 37/100 | — | — | -35.0% | +13.37% | $8.1M | /curx-vs-ensc → |
| MBRX Moleculin Biotech Inc. | E | 34/100 | — | — | -35.0% | +5.32% | $8.3M | /mbrx-vs-ensc → |
| TCRT Alaunos Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -10.26% | $8.1M | /tcrt-vs-ensc → |
| SNGX Soligenix Inc. | D- | 42/100 | — | — | -35.0% | +1.49% | $7.7M | /sngx-vs-ensc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001716947 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ensysce Biosciences Inc. (ENSC) reported GAAP revenue of $5.1M (-2.8% vs. FY2024 revenue of $5.2M , and +127.2% cumulative change since FY2023) , GAAP net income of -$10.2M, operating cash flow of -$7.8M, and free cash flow of -$7.9M (-5.7% YoY). On the balance sheet, ENSC closed FY2025 with $7.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.1M | -$10.2M | -$7.8M | -$7.9M | $7.5M | — |
| FY2024 (FY) | 2024-12-31 | $5.2M | -$8.0M | -$7.5M | -$7.5M | $5.6M | — |
| FY2023 (FY) | 2023-12-31 | $2.2M | -$10.6M | -$10.8M | -$10.8M | — | — |
3. ENSC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ENSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Ensysce Biosciences Inc. (NASDAQ: ENSC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $0.38 (-9.24% 1D, market cap $8.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ENSC ranks #812 in composite RQD confidence.
How does ENSC compare to CURX and MBRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENSC carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CURX (Curanex Pharmaceuticals Inc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $8.1M) and MBRX (Moleculin Biotech Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $8.3M). Among the 5-stock peer group, ENSC leads on earnings multiple (N/A) while ENSC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ENSC?
Per ENSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001716947), Ensysce Biosciences Inc. generated $5.1M in revenue (-2.8% YoY), -$10.2M in net income, and -$7.9M in free cash flow against $7.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ENSC trading relative to its 50-day, 200-day, and 52-week technical levels?
ENSC last traded at $0.38 (-9.24% on volume of 560,899 shares), positioning the stock -15.56% below its 50-day simple moving average ($0.45) and -11.63% below its 200-day simple moving average ($0.43). Across its 52-week range of $0.23 to $2.23, ENSC sits at the 7.5% percentile with a 14-day RSI of 41.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ SEC XBRL & RQD VERIFIED
ENSC — Ensysce Biosciences Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Ensysce Biosciences Inc. (ENSC) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.38 (-9.24% 1D, market capitalization $8.2M).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Ensysce Biosciences Inc. (ENSC) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B in the profile field and $8.5M in market data. Revenue of $5.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ensysce Biosciences Inc. (ENSC) reported $5.1M in annual revenue (up from $5.2M in FY2024, -2.8% YoY) and -$10.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.2M revenue, -$10.6M net income) through FY2025, ENSC scaled operating cash flow to -$7.8M and free cash flow to -$7.9M, backed by $7.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.23 – $2.23 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ENSC carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can ENSC sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $5.1M and free cash flow of -$7.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ENSC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ENSC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Ensysce Biosciences Inc. (ENSC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 21h ago
Ensysce Biosciences Stock Price Forecast. Should You Buy ENSC? StockInvest.us report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai Yahoo Finance report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Australia • 1d ago
Ensysce Biosciences, Inc. (ENSC) Seasonal returns chart Yahoo Finance Australia report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Ensysce Biosciences (ENSC) Slips 2.99% to $0.50 as Micro-Cap Biotech Tests Lower Support - IV Expansion Alert https://www.siam.in/ report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
Ensysce Biosciences (ENSC) Edges Higher: Shares Gain 2.19% to $0.44 - Hull Moving Average https://www.dars.gov.et/ report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Pasithea Therapeutics Corp. (KTTA) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST www.dars.gov.et • 1d ago
Ensysce Biosciences (ENSC) Gains 4.29% to $0.52 as Shares Press Toward Resistance - Put Wall www.dars.gov.et report covering Ensysce Biosciences Inc. (ENSC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 14d ago
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2 Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ENSC Bull vs. Bear Conversation Board — What's Your Call at $0.38?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENSC 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $0.54 (+28.6%)
📌 Pinned Debate The stock trades at $0.44 with a 52-week range of $0.23 to $2.23, leaving room for sharp rerating if the company restores positive cash
The street is overcomplicating Ensysce Biosciences Inc. (ENSC). The stock trades at $0.44 with a 52-week range of $0.23 to $2.23, leaving room for sharp rerating if the company restores positive cash generation from its $5.1M revenue base.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.45.
VolSurface_Trader 🐂 BULL
@ShortSeller_Dan Shorting a 9/20 institutional whale-flow stock at $0.42 is dangerous when funds are rotating into Health Care.
SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH
🎯 Target: $0.33 (-21.4%)
Spot @ $0.42 With ROIC at -35%, a Piotroski F-Score of 2 out of 9, and operating losses of $10.2M against $4.3M in cash, the balance sheet pillar sc
Sitting on the sidelines or leaning short ENSC above $0.42. With ROIC at -35%, a Piotroski F-Score of 2 out of 9, and operating losses of $10.2M against $4.3M in cash, the balance sheet pillar scores only 5 out of 20.. Until Fundamental Cash Engine (7/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.23.